Prescription Weight Loss Medication in Singapore: What Actually Works

For most of the last fifty years, the medical profession had very little to offer someone with obesity beyond advice they had already heard. Diet and exercise worked in trials and failed in life, largely because the body defends its weight with a hormonal response most people cannot out-discipline indefinitely. The arrival of GLP-1 receptor agonists changed that in a way few developments in general medicine have.

This guide explains what these medications are, how they work, who they are actually for, what results are realistic, what they cost in Singapore, and the question that matters most and gets asked least: what happens when you stop.

Why medication became a legitimate option

Obesity is now understood as a chronic, relapsing condition with strong biological drivers rather than a straightforward failure of willpower. When you lose weight, your resting metabolic rate falls disproportionately, the hunger hormone ghrelin rises, the satiety hormone leptin falls, and appetite increases and stays increased for years. This adaptive response is the reason regain rates after unsupported dieting are so high.

Medication does not remove the need for protein, resistance training and sleep. What it does is reduce the biological pressure working against you, making a sustained energy deficit tolerable rather than a daily act of endurance.

GLP-1 receptor agonists

GLP-1, glucagon-like peptide-1, is a hormone released by the gut after eating. It stimulates insulin release when glucose is high, suppresses glucagon, slows the rate at which the stomach empties, and acts on appetite centres in the brain. GLP-1 receptor agonists are engineered versions that resist rapid breakdown, so a single weekly injection sustains the effect.

The subjective experience most patients describe is not a suppressed appetite in the stimulant sense. It is quieter. Food stops occupying mental space. Portions that previously felt normal feel excessive. The urge to continue eating after satiety, and the background chatter about the next meal, both diminish.

Semaglutide

Semaglutide is a once-weekly injection, originally licensed for type 2 diabetes and subsequently for weight management at a higher dose. In the pivotal weight management trials, average loss was in the region of fifteen percent of body weight over sixty-eight weeks, with a substantial minority exceeding twenty percent. Dosing starts low and escalates over several months specifically to limit nausea.

Beyond weight, semaglutide has demonstrated cardiovascular benefit in people with established cardiovascular disease and overweight or obesity, which shifts it from a cosmetic intervention to a preventive one.

Tirzepatide

Tirzepatide acts on two receptors, GLP-1 and GIP, and has produced the largest weight reductions seen with any pharmacological treatment to date, averaging above twenty percent in trials at the higher doses. It is also a once-weekly injection with a similar side effect profile and a similar slow escalation schedule.

Oral options

Oral semaglutide exists and avoids injections, but absorption is poor and it must be taken fasted with a small amount of water and nothing else for thirty minutes, which many people find harder to sustain than a weekly injection.

Older and adjunctive medications

Orlistat blocks the absorption of a proportion of dietary fat in the gut. It produces modest penurunan berat badan, around three to five percent, and its side effects are directly proportional to how much fat you eat, which some patients find to be a useful behavioural feedback loop and others find intolerable.

Phentermine is an appetite-suppressing stimulant used for short-term treatment in selected patients. It can be effective but is not suitable for people with hypertension, cardiovascular disease, anxiety disorders or a history of substance misuse, and it is not a long-term strategy.

Naltrexone-bupropion acts on reward and appetite pathways in the brain and can be useful where emotional or reward-driven eating is prominent, though it carries its own contraindications.

Metformin is not a weight loss drug, but in people with insulin resistance or prediabetes it produces modest weight benefit alongside its metabolic effects, and is inexpensive.

Who is actually a candidate

Prescription weight management is generally considered when body mass index is 27.5 or above using Asian cut-offs, or from 25 upwards where obesity-related complications are present. Those complications include type 2 diabetes or prediabetes, hypertension, dyslipidaemia, fatty liver disease, obstructive sleep apnoea, polycystic ovary syndrome and osteoarthritis limiting activity.

Equally important is who these medications are not for. They are not appropriate in pregnancy or when trying to conceive, in people with a personal or family history of medullary thyroid carcinoma or MEN2 syndrome, in active pancreatitis, or in people with a history of an eating disorder without specialist involvement. They are also a poor fit for someone seeking to lose three kilograms before a holiday, and any clinic willing to prescribe on that basis is not practising medicine.

What to expect in practice

A proper assessment before prescribing should include weight, waist, blood pressure, HbA1c or fasting glucose, a lipid panel, liver and kidney function, thyroid function, and in men often testosterone, given how frequently it is suppressed by excess visceral fat. It should also include an honest conversation about diet, alcohol, sleep, training history and previous attempts.

Dose escalation is deliberately slow. Starting at the maintenance dose reliably produces nausea severe enough to make people stop. A typical schedule steps up every four weeks over three to five months, with review at each step.

Side effects

The common effects are gastrointestinal: nausea, reflux, constipation, occasionally vomiting or diarrhoea. Most are dose-related, worst in the days after an increase, and settle. They are substantially reduced by eating smaller portions, avoiding high-fat meals, stopping at the first sense of fullness and staying hydrated.

Less common but important issues include gallstones, particularly with rapid weight loss, and pancreatitis, which is rare but requires immediate assessment if severe persistent abdominal pain develops. Muscle loss is a genuine concern: a meaningful share of weight lost on these drugs is lean mass unless protein intake and resistance training are deliberately maintained. This is not a footnote, it is central to using them well.

Cost and access in Singapore

GLP-1 medications are prescription-only and are not inexpensive. Monthly cost varies with the drug, the dose and the pharmacy, and rises as you escalate to higher maintenance doses. Insurance coverage for weight management specifically is uncommon, though treatment for type 2 diabetes may be covered differently. Global supply has been intermittent over recent years, which occasionally affects availability of particular doses.

Anyone budgeting for treatment should plan for a horizon of at least a year rather than a month, because stopping early tends to undo the result.

The question that matters: what happens when you stop

Withdrawal studies are consistent and sobering. When GLP-1 treatment stops, appetite returns and a substantial proportion of the lost weight comes back within a year. This is not a flaw unique to these drugs. Blood pressure rises when antihypertensives stop, and nobody considers that a failure of the medication.

The practical implication is that these are treatments for a chronic condition, not a course of antibiotics. There are three reasonable paths: continued treatment at a maintenance dose, a planned taper onto a well-established lifestyle foundation with close monitoring, or continued treatment at reduced frequency. The wrong approach is stopping abruptly with no plan, which is where most of the disappointing outcomes come from.

Monitoring while on treatment

Starting a GLP-1 medication is not a one-off prescription handed over and left alone. A sensible monitoring schedule looks at both efficacy and safety at defined intervals, rather than waiting for a problem to announce itself.

At baseline, weight, waist circumference, blood pressure, HbA1c or fasting glucose, a lipid panel, liver and kidney function and, where relevant, testosterone are recorded. These are repeated at three months and again at six months, partly to track progress and partly because the metabolic improvements from weight loss, better glucose control, falling triglycerides, sometimes a rise in low testosterone, are the actual clinical goal, not the number on the scale.

Each dose increase should prompt a review, even a short one. This is when gastrointestinal tolerance, hydration, appetite and any early signs of gallbladder symptoms are checked. Persistent vomiting, inability to keep fluids down, or severe abdominal pain radiating to the back are not things to wait out until the next scheduled appointment; they warrant same-day contact with the prescribing doctor, because dehydration and pancreatitis are the two complications that escalate quickest if ignored.

Muscle mass is worth tracking directly rather than assumed. Bioimpedance analysis or simple strength benchmarks, how much you can lift, how many reps at a given weight, give an early warning if lean mass is falling disproportionately to fat mass. If it is, the response is usually to increase protein intake further and add resistance training volume rather than to stop the medication, since inadequate training input is a more common cause than the drug itself.

For men on longer courses, an annual review of bone density risk factors and a repeat testosterone check is reasonable, since substantial weight loss changes both. None of this monitoring is burdensome once it is scheduled in advance; it is the patients who treat the prescription as a set-and-forget event who tend to run into avoidable problems.

What makes treatment work

The patients who do best treat medication as the thing that makes the fundamentals possible, not a replacement for them. That means protein at roughly 1.6 grams per kilogram, which becomes harder as appetite falls and needs deliberate planning. Resistance training twice weekly to protect lean mass. Seven hours of sleep. Alcohol kept genuinely low. And a review schedule with blood markers repeated at three and six months, so the outcome being measured is metabolic health rather than a number on a scale.

Related reading: obesity and metabolic risk, how weight management improves your health, and weight loss and healthspan.

Frequently Asked Questions

Q: How much weight can I expect to lose on a GLP-1 medication?

A: Trial averages are around fifteen percent of body weight for semaglutide and above twenty percent for tirzepatide at higher doses, over roughly a year to eighteen months. Individual results vary widely, and outcomes are consistently better in people who maintain adequate protein intake and resistance training alongside the medication rather than relying on it alone.

Q: Will I regain the weight if I stop?

A: A significant proportion of it, usually, unless there is a plan. Withdrawal studies show appetite returns and much of the loss reverses within a year of stopping. This is why treatment is best framed as management of a chronic condition, with either continued maintenance dosing or a supervised taper onto an established routine rather than an abrupt stop.

Q: Are these medications safe?

A: They have a well-characterised safety profile from large trials and extensive clinical use. Gastrointestinal side effects are common and usually manageable with slow dose escalation. Gallstones and pancreatitis are uncommon but real risks that require awareness and prompt review. They are unsuitable in pregnancy and in people with a history of medullary thyroid cancer, which is why prescribing requires proper assessment.

Q: Can I get weight loss medication in Singapore without seeing a doctor?

A: No. These are prescription-only medicines and require a medical consultation, baseline blood tests and ongoing monitoring. Products sold online without a prescription are either not what they claim to be or are being supplied outside proper medical oversight, and both carry real risk.

Q: Do I still need to diet and exercise?

A: Yes, and arguably more deliberately than before. Because appetite falls sharply, hitting protein targets requires planning rather than happening by default. Without adequate protein and resistance training, a large share of the weight lost is muscle, which lowers metabolic rate and makes long-term maintenance harder.

Q: How long before I see results?

A: Most people notice reduced appetite within the first two weeks, though meaningful weight change usually becomes visible from around week four to eight as doses escalate. The largest reductions typically occur between months three and twelve. Judging the treatment at week three, while still on a starting dose, gives a misleading picture.

Book a medical weight management consultation at our Orchard clinic or speak to a doctor about whether prescription treatment is appropriate for you.